Department of Clinical Dermatology; Center for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Dermatol Ther. 2021 Jan;34(1):e14584. doi: 10.1111/dth.14584. Epub 2020 Dec 6.
Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin-17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or more of the above-cited drugs, real-life data on the effectiveness of switching to one anti-interleukin-23 biologic (guselkumab, risankizumab, or tildrakizumab) are very scarce. Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug.
在最近可用于治疗银屑病的生物药物中，针对白细胞介素-17（司库奇尤单抗和依奇珠单抗）或其受体（布罗达单抗）的药物已被证明具有快速疗效。然而，对于那些已经对上述一种或多种药物产生耐药的患者，关于将其转换为一种抗白细胞介素-23 的生物制剂（古塞库单抗、瑞莎珠单抗或替西珠单抗）的真实世界数据非常有限。在这里，我们报告了我们在治疗 12 例多药耐药银屑病患者方面的经验，这些患者在接受抗白细胞介素-17 药物转换为抗白细胞介素-23 药物后，经过 6 个月的前瞻性随访，银屑病得到了显著改善。
